Thomas Jefferson University

Jefferson Digital Commons
Department of Neurology Faculty Papers

Department of Neurology

1-1-2020

Conditions for combining gene therapy with bone marrow
transplantation in murine Krabbe disease.
Mohammad Rafi
Department of Neurology, Sidney Kimmel College of Medicine, Thomas Jefferson University, Philadelphia,
PA 19107, United States

Paola Luzi
Department of Neurology, Sidney Kimmel College of Medicine, Thomas Jefferson University, Philadelphia,
PA 19107, United States

David A Wenger
Department of Neurology, Sidney Kimmel College of Medicine, Thomas Jefferson University, Philadelphia,
PA 19107, United States

Follow this and additional works at: https://jdc.jefferson.edu/neurologyfp
Part of the Neurology Commons, and the Translational Medical Research Commons

Let us know how access to this document benefits you
Recommended Citation
Rafi, Mohammad; Luzi, Paola; and Wenger, David A, "Conditions for combining gene therapy with
bone marrow transplantation in murine Krabbe disease." (2020). Department of Neurology
Faculty Papers. Paper 218.
https://jdc.jefferson.edu/neurologyfp/218
This Article is brought to you for free and open access by the Jefferson Digital Commons. The Jefferson Digital
Commons is a service of Thomas Jefferson University's Center for Teaching and Learning (CTL). The Commons is
a showcase for Jefferson books and journals, peer-reviewed scholarly publications, unique historical collections
from the University archives, and teaching tools. The Jefferson Digital Commons allows researchers and interested
readers anywhere in the world to learn about and keep up to date with Jefferson scholarship. This article has been
accepted for inclusion in Department of Neurology Faculty Papers by an authorized administrator of the Jefferson
Digital Commons. For more information, please contact: JeffersonDigitalCommons@jefferson.edu.

B

BioImpacts

Rafi MA., et al., BioImpacts, 2020, 10(2), 105-115
doi: 10.34172/bi.2020.13
http://bi.tbzmed.ac.ir/

TUOMS

TUOMS

PRESS

PRESS

Publish Free

ccess

Conditions for combining gene therapy with bone marrow
transplantation in murine Krabbe disease
Mohammad A. Rafi ID , Paola Luzi, David A. Wenger*

ID

Department of Neurology, Sidney Kimmel College of Medicine, Thomas Jefferson University, Philadelphia, PA 19107, USA
Article Info

Article Type:
Original Article
Article History:
Received: 2 Feb. 2020
Accepted: 17 Mar. 2020
ePublished: 24 Mar. 2020
Keywords:
Krabbe disease
AAVrh10 gene therapy
Twitcher mice
Bone marrow transplantation
Combined therapy
Myelination

Abstract
Introduction: Krabbe disease (KD) is an
autosomal recessive lysosomal disorder caused
by mutations in the galactocerebrosidase
(GALC) gene. This results in defective
myelination in the peripheral and central
nervous systems due to low GALC
activity. Treatment at this time is limited
to hematopoietic stem cell transplantation
(HSCT) in pre-symptomatic individuals.
While this treatment extends the lives of
treated individuals, most have difficulty
walking by the end of the first decade due to
peripheral neuropathy. Studies in the murine model of KD, twitcher (twi) combining bone marrow
transplantation (BMT) with AAVrh10-mGALC showed a great extension of life from 40 days to
about 400 days, with some living a full life time.
Methods: In order to find the optimum conditions for dosing and timing of this combined
treatment, twi mice were injected with five doses of AAVrh10-mGALC at different times after
BMT. Survival, as well as GALC expression were monitored along with studies of sciatic nerve
myelination and possible liver pathology.
Results: Dosing had a pronounced effect on survival and measured GALC activity. There was
window of time after BMT to inject the viral vector and see similar results, however delaying both
the BMT and the viral injection shortened the lifespans of the treated mice. Lowering the viral
dose too much decreased the correction of the sciatic nerve myelination. There was no evidence
for hepatic neoplasia.
Conclusion: These studies provide the conditions optimum for successfully treating the murine
model of KD. There is some flexibility in dosing and timing to obtain a satisfactory outcome. These
studies are critical to the planning of a human trial combining the “standard of care”, HSCT, with a
single iv injection of AAVrh10-GALC.

Introduction
Krabbe disease (KD) or globoid cell leukodystrophy
(GLD; OMIM 245200) is an autosomal recessive disorder
affecting myelination in the human patients. It is caused
by the deficiency of galactocerebrosidase (GALC; EC
3.2.1.46) activity resulting from mutations in the GALC
gene.1 The incidence is about one in 100 000 births in
the United States. While most human patients present
in infancy or late infancy, later onset patients are also
diagnosed. In addition to human patients, genetic
mutations in the GALC gene have resulted in GLD
in several animal species, including mice, dogs and

rhesus monkeys.2 Affected animals also have very low
GALC activity resulting in pathology similar to human
patients. Colonies of these species have been established
at various locations to use for treatment trials. These
include bone marrow transplantation (BMT), enzyme
replacement therapy, gene therapy via different routes
of administration, substrate reduction therapy, chemical
chaperone therapy, small molecule therapy including
anti-inflammatory drugs and combinations of these
approaches.3-21 These different approaches have resulted
in variable degrees of success. Some of these trials only
resulted in minimal extension of life, and significant

*Corresponding author: David A. Wenger, Email: david.wenger@jefferson.edu

© 2020 The Author(s). This work is published by BioImpacts as an open access article distributed under the terms of
the Creative Commons Attribution License (http://creativecommons.org/licenses/by-nc/4.0/). Non-commercial uses of the work are
permitted, provided the original work is properly cited.

Rafi et al

side effects and pathological events were noted. Other
treatments involving multiple injections into the brain,
BMT without myeloablation of the recipient and use of
toxic chemicals for substrate reduction that probably will
not be used in human patients. Obviously, because of the
cost and ease of breeding, most of the therapy trials have
been done using the twitcher (twi) mouse model. As early
as 1984, Yeager et al3 demonstrated that transplantation
of BM cells from wild type mice into twi mice resulted in
an extension of life from about 40 days when untreated to
about 80 days. Early studies were done using irradiation
for myeloablation to prepare the mice for BMT. However,
for several reasons busulfan is now more commonly used
for myeloablation.22
The initial purification of human GALC and cloning
of the human GALC cDNA by this laboratory in 199323,
24
was followed by characterization of the gene in 1995.25
This opened the way to additional studies including
mutational analysis of patients. Over 250 disease-causing
mutations have been identified in the GALC gene (http://
www.hgmd.cf.ac.uk). The identification of the diseasecausing mutations in the animal species has facilitated the
establishment of colonies for research on the pathology
and treatment of this disease. Having GALC clones has
also led to in vitro and in vivo gene therapy studies. Initial
studies showed that the GALC cDNA in a retroviral vector
could transduce GALC-deficient cells resulting in supranormal GALC activity with no ill effects, and that GALC
activity could be excreted by these cells and taken up by
neighboring cells.26 The idea of cross correction is the basis
for studies showing that transplanted or virally transduced
cells can supply a missing enzyme to neighboring cells,
especially in lysosomal disorders.27 Since that time several
groups have placed the species-specific GALC cDNA into
different viral vectors for in vivo gene therapy trials alone
and in combination with other approaches. It appears that
adeno-associated viral vectors are being used most often
in animal studies for KD and other genetic disorders.28,
29
In this laboratory AAVrh10 containing the mouse
GALC cDNA is being used for gene therapy studies in twi
mice.14,16,17 Initial studies using this vector involved intracerebroventricular, intra-cerebellar and intra-venous (iv)
injections on PND2.14 There was a significant extension
of life when all three routes of administration were used;
the median survival was about 100 days compared to
40 days in untreated mice. There was clear evidence for
GALC expression throughout the brain and improved
myelination. Also, there was retention of walking, strength,
and mobility until the end of life. While the results were
positive they clearly were not good enough. Further
studies using a single iv injection of AAVrh10-mGALC
on PND10 showed dramatic improvement in central and
peripheral nerve system myelination, an area significantly
affected in human patients and animal models.16 Starting
iv treatment on PND10 instead of PND2 resulted in a
longer lifespan for the treated mice, although it was still
106
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less than 100 days. PND10 is when mice start to rapidly
myelinate, they are bigger and a larger dose of vector can
be given. This may also reflect more the delay in treating
newborn infants before receiving a definitive diagnosis of
KD after birth.
The standard of care in pre-symptomatic infants and
mildly affected later-onset patients with KD is HSCT.30,31
While initial studies were done using bone marrow cells,
more recently HSCs isolated from umbilical cord blood are
being used. This greatly improves the chances of finding
a suitable match for a given patient. While this treatment
has been shown to increase the lifespan of treated patients,
almost all treated patients present with difficulty walking
by the end of the first decade of life and have problems
with expressive language.32 The walking difficulties appear
to be due to a failure of HSCT to adequately correct the
peripheral nervous system. Our studies in twi mice
using a single iv injection of AAVrh10 containing mouse
GALC cDNA alone at about PND10 showed near normal
myelination in sciatic nerves. Moreover, studies combining
BMT with a single iv injection of AAVrh10-mGALC
on PND10-11 showed great synergy with many treated
mice still alive at 350 days at the time of publication.17
This compares to the median survival of 75-80 days for
BMT or AAVrh10-mGALC when given alone. In order to
evaluate the dose of viral vector that would be effective
and to determine the timing of the combined treatment
and the time from the BMT to viral injection, additional
studies were undertaken. Results presented here show that
the dose of vector is critical to survival and that there is
some flexibility in the timing to perform viral injection
treatment after BMT. These studies are very important
since the combination of HSCT, the standard of care in
humans, with a single iv injection of AAVrh10-hGALC is
being considered by the FDA for a human trial.
Materials and Methods
Study design
This study is a follow up of our previous studies on gene
therapy in combination with BMT for the mouse model
of the KD. While we and others have shown a synergistic
effect of AAV gene therapy in combination with
BMT,9,12,14,17,18,20,21 the focus of this study was to investigate
treatment conditions for safe and more effective therapy.
Experimental variables examined include viral dosage,
timing for both viral injection and BMT and use of bone
marrow cells from heterozygous donors.
Generation of AAVrh10-mGALC vector
Construction of the viral vector used in this study was
previously reported.16 Briefly, pCB7plasmid, an enhanced
construction of AAV2 vector, was received from the
Institute for Human Gene Therapy at the University
of Pennsylvania. Mouse GALC cDNA was cloned into
EcoRI site of this construct, downstream from the human
CMV-enhancer/chicken β-actin hybrid promoter. The
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construct was sequenced and the integrity of the ITRs
was confirmed by restriction enzyme analysis using
SmaI and NcoI. The functionality of the construct was
verified by in vitro cell transfection and measurement
of GALC enzyme activity. The recombinant genome
was cross-packaged into AAVrh10 capsid by utilizing a
chimeric AAV2-Rep/AAV1-Cap and helper plasmids
during a triple-transfection procedure.33,34 Viral packaging
and purification were accomplished by the Institute
for Human Gene Therapy and the vector was called
AAVrh10-mGALC. Viral titer, was determined by PCR of
the simian virus 40 poly(A) sequence.34,35 The viral titer
of the vector batch of AAVrh10-mGALC in use is 6×1013
genomic equivalents/mL.
Animal procedures
Studies in mice were performed in accordance with
approved protocols from the Animal Care and Use
Committee at Jefferson Medical College. Twi mice used
in the study were originally obtained from the Jackson
Laboratory. These mice with a W339X mutation in the
GALC gene are in the C57BL/6 background. Genotyping
of the mice was performed on PND1 using polymerase
chain reaction (PCR) as previously described.14,36 Toe clips
were used for mouse identification and DNA extraction.
PCR fragments were digested with EcoRV and analyzed
by electrophoresis on 2.5% MetaPhor agarose gel (Lonza
Inc. Allendale, NJ, USA). Male and female mice were used
arbitrarily, even before their sex could be determined. No
sex-related differences in outcomes following treatment
were noted. Transplanted animals were monitored daily
for the first week for any signs of problem related to the
procedure. They were monitored two to three times a
week for the rest of their lives. Body weight was recorded
weekly throughout their lives. Treated mice were allowed
to survive as long as humanely possible or sacrificed at
different time points for analysis. If deemed moribund
(inactive and with unexpected weight loss) the mice were
killed by carbon dioxide euthanasia and the age of death
was recorded.
Bone marrow transplantation
The procedure for BMT was previously described.17
Briefly, BMT recipient mice were myelo-suppressed
using busulfan (Sigma, St. Louis, MO). A 3 mg/ml
solution of busulfan was prepared by dissolving it in
dimethylsulfoxide (30% of the final volume), and adding
the remaining volume of sterile phosphate-buffered
saline. Eight or 9-day-old affected mice (this small
variability in injection times was due to the timing of
births) were weighed, and 30 mg/kg of body weight of
the busulfan solution was injected intraperitoneally (ip).
BM cells from the syngeneic donor mice were obtained by
flashing tibiae and femora using ice-cold Hepes buffered
Hanks’ balanced salt solution (Mediatech, Manassas, VA).
The cells were counted, centrifuged, and resuspended in

Dulbecco's modified Eagle's medium. Twenty-four hours
after busulfan injection, mice received an ip injection of
3–4 × 107 BM cells in a total volume of 0.2 mL. For at
least two weeks after BMT, the mice were provided with
prophylactic Neomycin (final concentration 500 μg/mL)
(Sigma) in drinking water. Mice that received BMT and
died less than PND30 were not included in these studies.
Initially BM cells from non-carrier donors were used, but
in some later studies BM cells from carrier mice were used.
Viral delivery
The young mice were cryo-anesthetized on ice before the
injections. Injections were carried out on a light box to
facilitate visualizing the tail vein. In our original publication
a total of 4 × 1013 gc/kg body weight of virus were injected
into the tail vein using a 28G insulin syringe.17 The needle
was inserted into the vein, and the solution containing the
virus was injected manually. The success of injection was
verified by noting blanching of the vein. The time for viral
injection was between PND10 and PND40 depending the
parameter to be investigated. After the injection, pups
were warmed and returned to their cage. Mice that died
within a few days of the injection (less than 10%) were not
included in this study.
Tissue preparation for GALC assay
Tissues from treated and untreated mice were removed
immediately after carbon dioxide euthanasia. The tissues
were quickly frozen and stored at −80°C or immediately
homogenized in distilled water using a Polytron apparatus
(Brinkmann Instruments, Westbury, NY). Protein
concentration was determined according to the method
of Lowry et al.37 GALC activity was measured using [3H]
galactosylceramide substrate, according to our published
method.38 GALC activity was expressed as nmol substrate
hydrolyzed/h/mg protein.
Preparation of semi-thin sections of sciatic nerves and
toluidine blue staining
Treated and control mice were sacrificed by carbon dioxide
euthanasia. Sciatic nerves were removed and submerged
into 2% glutaraldehyde in 0.1M phosphate buffer, pH 7.4,
followed by post-fixation in 1% osmium tetroxide in 0.1M
phosphate buffer. The tissue fragments were dehydrated
in series of graded ethanol penetrated with mixtures of
embedding medium (Spurr) and ethanol and polymerized
over night at 80°C. Semi-thin (0.5 micron) sections were
cut on a UC7 ultramicrotome (Leica Microsystems,
Wetzlar, Germany), using glass knives. The sections were
transferred to glass microscopic slides, and stained with
Toluidine Blue O.
Hematoxylin and eosin stain of liver sections
Livers were removed from untreated and treated mice,
fixed in 10% formalin and paraffin-embedded. Four
micrometers thick sections were cut on a microtome
BioImpacts, 2020, 10(2), 105-115
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at room temperature, mounted on Superfrost Plus
microscope slides (Thermo-Fisher Scientific), and airdried. Sections were de-paraffinized in xylene, re-hydrated
in a series of graded ethanol, and distilled water. Sections
were stained with hematoxylin and eosin (H&E) using the
manufacturer’s protocol. After staining and final washes,
slides were mounted in ProlongGold (Life Technologies)
and covered with a coverslip for examination.
Statistical analysis
Survival analysis was performed using GraphPad Prism
7.0 software (GraphPad software Inc., San Diego, USA).
The survival curves were analyzed using the log-rank
(Mantel-Cox) test. The survival rates of all experimental
groups were compared to our previously published
method where the mice received BMT around PND10
and iv viral injection (4 × 1013 gc/kg body weight) on the
following day. GALC activity of the CNS and PNS of the
mice treated with different viral doses were compared to
the standard viral dose using two-tailed, unpaired t test (*
P < 0.05, **P < 0.01, *** P < 0.001, **** P < 0.0001).
Results
Update on the previously published method of treatment
combining BMT and iv AAVrh10-mGALC
Intra-peritoneal (ip) injection of the affected mice at
PND9 with busulfan (30 mg/kg body weight) was followed
after 24 hours by an ip injection of 3-4 × 107 bone marrow
cells from non-carrier syngeneic mice. The following
day mice received an iv injection of 4 × 1013 gc/kg body
weight (called 1X dose) of AAVrh10-mGALC [17]. At
the time of that publication most of the treated mice were
still living, and additional mice were treated in the same
manner. On Fig. 1 the survival of untreated twi mice and
mice treated with combined therapy are compared to mice
receiving BMT alone or AAVrh10 alone. As can be seen on
the figure the median age of survival of the mice treated
with combined therapy is nearly 400 days with some living
over 500 days compared to 40 days if untreated. Due to
the known tropism of AAVrh10, the heart was found
to have the highest GALC activity followed by skeletal
muscle, liver, sciatic nerve, spinal cord and cerebellum
using the standard dosing and timing (Fig. 2A and B,
black bar). However, while the GALC activities measured
in nervous tissues are lower than heart, liver and muscle
they are within the range measured in wild type mice and
well above the very low activity measured in untreated
twi mice. The GALC activities are maintained in all tested
tissues for the life of the treated mice (Table 1).
As shown in the previous publication17 luxol fast blue/
periodic acid Schiff (LFB/PAS) staining showed normal
myelination of the CNS and PNS for the lives of the
treated mice. Grossly the sciatic nerves of the untreated
twi mice are enlarged due to edema (Fig. 3B), while they
look thin like normal in twi mice receiving BMT plus AAV
(Fig. 3C). The lack of normal myelination plus edema is
108
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Fig. 1. Effect of different treatment strategy on twi mice. Survival of twi
mice either untreated, treated with BMT only, AAVrh10-mGALC only and
combined BMT plus AAVrh10-mGALC on PND10/11 using the standard 1X
dose. ****P < 0.0001.

Fig. 2. Effect of the viral dose on GALC activity of different tissues
in twi mice. All BMT and viral injections were performed on PND10/11.
(A) GALC activities in brain, cerebellum, spinal cord and sciatic nerve of
twi mice receiving BMT and the standard 1X dose of vector are shown by
the solid black bar (n=11-13). The following viral doses were used: 1/2X
(n=6), 1/10X (n=4), 1/100X (n=5) and 4X (n=12-13). GALC activities were
compared to the standard dose. Two-tailed, unpaired t test was used for
statistical analysis. *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001 (B)
Effect of the viral dose on GALC activities of heart, skeletal muscle and
liver is compared with our standard treatment (black bar). As shown in the
figure, the GALC activity of the heart was highest compared to skeletal
muscle and liver. As the GALC activities were so high in these tissues
compared to the untreated twi mice and wild type mice statistical analysis
was not performed. The mean and SEM is presented.

confirmed on toluidine blue stained semi-thin sections
of sciatic nerve from an untreated twi mouse (Fig. 4B)
compared to a wild type mouse (Fig. 4A). A 606-day-old
twi mouse treated with combined therapy using standard
dosing and timing shows normal myelinated axons with
no edema (Fig. 4C). Normal myelination in the sciatic

Combined gene therapy with bone marrow transplantation in Krabbe disease
Table 1. GALC activitya of different organs at different ages of mice treated with BMT and 1X AAV

Mice age (days)
100-300
300-500
500-750
a
nmol/h/mg protein.

Number of mice
n=3
n=5
n=3-5

Tissues
Brain
0.7-1.9
0.7-2.2
1.1-3.6

nerve is important as this tissue is not corrected by HSCT
alone in human patients and twi mice.
Effect of viral dose following BMT on survival, GALC
activity and myelination of twi mice
In order to see the effect of viral dose on survival, different
doses of AAVrh10-mGALC were injected iv 24 hours
following BMT as described above. Initial studies were
done using the following viral doses: 4 × 1013 (1X), 2 ×
1013(1/2X), 4 × 1012 (1/10X) and 4 × 1011 (1/100X) gc/
kg body weight. The p values compare the survival of
mice receiving different viral doses to the standard dose
(1X). As can be seen on Fig. 5A injecting one-half of the
published viral dose the median survival dropped to about
180 days (P = 0.01) about half of the median survival when
the standard dose was used. When one-tenth of the usual
dose was used the median survival was only about 80
days (P = 0.0001), and when one-hundredth of the usual
dose was used there was essentially no effect on survival
beyond untreated or BMT-treated twi mice showing the
dramatic effect of viral dose on survival. When the dose
of viral vector was increased to four times the published
dose, now 1.6 × 1014 (4X), the median survival, while not
statistically significant, was over 500 days, again showing
the importance of viral dose on survival after BMT in the
twi mice.

Fig. 3. Gross appearance of sciatic nerves in wild type and
untreated and treated twi mice. (A) Sciatic nerves from a 60-day-old
wild type mouse. (B) 37-day-old untreated twi mouse. (C) 250-day-old
mouse treated with both BMT and AAVrh10-mGALC on PND10/11 using
the standard 1X dose.

Sciatic nerve
1.3-2.3
2.7-6.5

Liver
5.6-47.0
14.5-37.9
31.0-75.0

Heart
111.0-625.1
396.6-712.2
238.8-627.8

In addition to the decreased survival with a viral dose
lower than the standard dose, there was a decrease in
GALC activity in the tissues tested (Fig. 2A, B). P values
presented on the figure compare the GALC activities
measured with the standard dose (1X) to the activities
measured with changes in the viral dose. The effects of
viral dose following BMT on GALC activities in nervous
tissues are shown on Fig. 2A. There was a statistically
significant drop in GALC activity in brain, cerebellum
and spinal cord with the 1/2X, 1/10X and 1/100X doses. In
sciatic nerve the GALC activities measured were also lower
at the smaller vector doses although they only reached
statistical significance at the 1/10 and 1/100X doses. When
the 4X dose was injected following BMT, GALC activities
were increased in all nervous tissues but did not reach
statistical significance in the spinal cord and sciatic nerve.
However, all doses resulted in much higher GALC activity
than untreated twi. These results show the ability of this
treatment to bring GALC activity to the needed tissues.
As expected, due to the tropism of AAVrh10, high GALC
activity was measured in heart, liver and skeletal muscle
(Fig. 2B). Very high GALC activity was measured in those
tissues using the three highest viral doses.
The condition of the sciatic nerve myelin was examined
using toluidine blue staining. Using the standard dose
of viral vector the sciatic nerve myelin looks normal in
a 606-day-old mouse (Fig. 4C) and a 239-day-old mouse
that received 4X the standard dose (Fig. 4D). The myelin
looks slightly less normal when 1/2X dose was used (Fig.
4E) and very abnormal when only 1/100X dose was
injected (Fig. 4F). The results clearly show that the dose of
AAVrh10-mGALC after BMT is critical to overall survival
as well as the health of the myelin in sciatic nerve.
Effect of the timing of the viral injection following BMT
on PND10
Initially twi mice were given busulfan on PND 9-10
and BMT the next day followed 24 hours later by an iv
injection of the viral vector.17 However, in this study the
standard dose of virus was injected five days, ten days or
30 days after the BMT. As can be seen in Fig. 5B, there was
no significant difference in survival when the viral vector
was injected five and 10 days after the BMT compared
to one day after BMT. The sciatic nerve myelin looked
completely normal when the viral vector was injected five
days after BMT (Fig. 4G) but less than completely normal
when injected 10 days after BMT (Fig. 4H). However, the
BioImpacts, 2020, 10(2), 105-115

109

Rafi et al

Fig. 4. Toluidine blue-stained semi-thin sections of sciatic nerves from wild type and untreated and treated twi mice. (A) 62-day-old wild type mouse.
(B) 36-day-old untreated twi mouse. (C) 606-day-old twi mouse treated with AAVrh10 (1X dose) on PND11. (D) 236-day-old twi mouse treated with AAVrh10GALC (4X dose) on PND11. (E) 235-day-old twi mouse treated with AAVrh10 (1/2X dose) on PND11. (F) 50-day-old twi mouse treated with AAVrh10 (1/100X
dose) on PND11. (G) 332-day-old twi mouse treated with AAVrh10 (1X dose) on PND15. (H) 420-day-old twi mouse treated with AAVrh10 (1X dose) on
PND20. All treated mice received BMT on PND10 followed by a single iv viral injection. Original magnification is 400X.

lifespans of the treated mice at these two time points were
very similar (Fig. 5B). Injecting the virus 30 days after
the BMT (PND40) resulted in a poor outcome, with the
median survival near that of mice receiving BMT alone
with only a few mice living more than 100 days (Fig.
5B). The GALC activities in the tissues of the mice in the
timing study are presented on Table 2. At all-time points
of viral injection there is high GALC activity in heart and
liver and less, but significant, activity in brain and sciatic
nerve. These studies indicate that damage to the nervous
system must have occurred before the increase in GALC

activity was provided by the injections of viral vector.
The question of how long does it take after vector
injection to measure GALC expression in different tissues
was answered by iv injection of 4 × 1013 gc/kg virus on
PND11 with or without BMT into twi mice. Samples
of heart, liver, brain and sciatic nerve were taken from
sacrificed mice and assayed for GALC activity 24, 48, 72
and 96 hours after viral injection. As can be seen on Table
3 higher than normal GALC activity was measured after
only 48 hours in heart and liver. Normal GALC activity
could be measured in sciatic nerve after 48 hours, and

Fig. 5. Survival of twi mice either untreated or treated under different conditions.
(A) Effect of viral dose on survival. (B) Effect of timing of viral injection (1X dose) after BMT on PND11. (C) Effect of doing both BMT and viral injection (1X
dose) at a later time point. (D) Effect of using heterozygote donors for BMT followed by AAVrh10 (1X dose) on PND11. The survival curves were analyzed
using the log-rank test. The survival of all experimental groups were compared to the standard method (solid blue color). **P < 0.01, ****P < 0.0001.
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Table 2. Effect of viral injection time on GALC activitya of the different tissues
BMT & Viral injection time B

Brain

Sciatic nerve

Liver

Heart

Muscle

Age (days)

Untreated affected, n = 6

0.24 (0.0-0.6)

0.2 (0.1-0.3)

0.5 (0.1-0.8)

0.5 (0.2-1.1)

0.5 (0.0-1.3)

30-45

Wild type, n = 4-6

1.8 (1.0-2.5)

1.2 (0.7-2.0)

1.9 (1.2-2.6)

0.6 (0.3-0.8)

0.4 (0.4-0.6)

32-90

AAV @ PND11-12, n=11-13

1.7 (0.5-3.6)

3.4 (1.3-8.6)

33.1 (13.0-75.0)

516.0 (140.0-758.0)

161.7 (51.0-433.2)

263-754

AAV @ PND15, n=5

2.0 (1.3-2.6)

7.9 (2.3-22.9)

73.0 (35.7-159.0)

550.1 (218.9-764.0)

124.7 (22.9-247.5)

90-647

AAV @ PND20, n=7

1.8 (0.8-3.4)

3.5 (1.5-5.4)

60.0 (18.4-100.7)

421.0 (95.9-657.6)

94.4 (9.5-222.2)

233-495

AAV @ PND40, =4

1.1 (0.7-1.7)

3.5 (1.2-3.6)

135.0 (70.5-255.7)

218.0 (115.4-324.2)

9.1 (2.7-12.7)

53-287

nmol/h/mg protein expressed as mean and range.
b
All treated mice received BMT on PND10 followed by 1X viral dose at different times.
a

Table 3. Time of GALC expressiona after iv injection of AAVrh10-mGALC on PND11

Organ

24 h

48 h

72 h

96 h

Untreated twi mice

Brain

0.3, 0.3

0.4, 0.2, 0.4 b

0.6, 0.7

1.1 b, 1.5 b

0-0.1

1.0-3.6

0, 0.2

2.2, 1.9, 1.9 b

5.5, 7.9

17.2 b, 41.1 b

0-0.2

0.7, 2.0

Liver

0.8, 0.9

14.2, 20.6, 20.7 b

18.0, 36.9

58.8 b, 71.8 b

0.1-0.3

1.7, 4.4

Heart

0.4, 0.4

13.1, 11.2, 12.3

23.8, 28.8

70.4 , 65.3

0.3-0.6

0.4-2.1

Sciatic nerve

a

b

b

b

Wild type

nmol/h/mg protein; b These mice also received BMT on PND10.

supranormal GALC activity could be measured after 72
hours. Busulfan treatment and BMT had no effect on the
rapid increase in GALC activity in the tissues analyzed.
Effect on survival when both BMT and viral injection are
performed later
When treatment with busulfan and BMT were delayed
until about PND17 and AAVrh10-GALC was injected the
following day there appeared to be a drop in the median
age of survival compared to when BMT plus AAVrh10
injection was performed about PND10-11, although it
did not reach statistical significance (Fig. 5C). If the start
of treatment was delayed until PND19-20 or PND21-22
there was a very significant drop in survival to less than
100 days. Since the tremor in untreated twi mice begins
on about PND20 it appears that starting treatment too
close to that age is not as effective as starting treatment at
a younger age. This highlights the importance of starting
BMT at a young age. Even, as shown above, GALC activity
can be measured in critical tissues very rapidly after iv
injection, it may be too late to correct damage that has
already occurred.
Effect when bone marrow cells from heterozygous donors
are used for transplantation before viral injection
Studies in humans show that HSCT alone has a positive
effect on lifespan and partial correction or stabilization
of some neurodiagnostic parameters. The effect of HSCT
alone is more successful in human patients with survival
into the second decade possible following HSCT if the
individual is treated when pre-symptomatic or very early
symptomatic.32 BMT treatment alone in twi mice extends
their lives from about 40 days to about 80 days, which
is not as great of an effect as seen in human patients. In
most human patients the HSC donor is a closely human

leukocyte antigen (HLA) matched allogeneic donor
obtained from umbilical cord blood. In some cases, HSC
from a related donor is used. In either case, it is ideal for the
donor to have good GALC activity so that engrafted cells
can donate GALC activity to neighboring cells. In addition
to these donor HSCs providing a source of GALC activity
it is thought that they also have an anti-inflammatory
component. However, it is possible with the increasingly
diverse human population in the United States that a
suitable allogeneic donor may not be available. A relative
who is a suitable HLA match but is a carrier of KD may
be the best option. Since AAVrh10-mGALC has a strong
synergistic effect when combined with BMT in the mice,
and the AAVrh10-GALC provides more GALC activity
than the BMT, it was thought that using heterozygous
donor mice as a source of BM cells would be equally as
good as non-carrier donors. As shown on Fig. 5D, the use
of BM cells from carriers lowered the median survival to
less than 200 days. The survival was similar to the survival
observed when half of the usual dose of AAVrh10 was used
in combination with BMT (Fig. 5A). However, the GALC
activities in the tissues from the twi mice treated using
BM cells from heterozygous donors and gene therapy are
similar to values measured in tissues from twi mice treated
using non-carrier donors (data not shown). While this is
an interesting finding in the twi mice, its relevance to the
use of carrier donors in humans is still open to question. It
is also well known that there are common polymorphisms
in the GALC gene that lower the GALC activity measured
in leukocytes to values measured in obligate carriers. It is
probable that some human patients receiving HSCT were
transplanted with HSC from a donor having one or more
of these enzyme-lowering polymorphisms. What effect
this has on overall outcome is not known.
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Pathological examination of liver sections from treated
twi mice
In twi mice treated with combined BMT and iv gene therapy
that died or were sacrificed less than 300 days of age all
organs appeared normal on gross examination, including
the heart and liver with high GALC activity. Liver samples
from mice treated by different methods were taken, sliced
and stained with H&E for pathological examination.
While most regions of the liver samples from long-living
treated mice appeared normal (Fig. 6A), pathological
changes were noted in the livers of a few animals, notably
dilated sinusoids (Fig. 6B), hepatocellular hyperplasia
(Fig. 6C) and presence of vacuolar cytoplasmic aggregates
(Fig. 6D). Rare foci of extra-medullary hematopoiesis
were also noted. Similar changes have been reported in
some patients receiving blood stem cell transplantation
and with other hematological disorders.39 There have
been reports of hepatocellular carcinoma in livers of mice
treated with AAV vectors.40-43 However, the examination
of liver tissues from over 50 treated mice showed no
evidence of neoplastic changes.
Discussion
The naturally occurring twi mouse has proven to be an
excellent model to study the pathology and treatment of
KD. It has a mutation causing a premature stop codon
resulting in little if any GALC protein to be made.36 Mice
homozygous for this mutation die by about 40 days and are
not fertile. Since the initial attempt at treating this model
with BMT by Yeager and colleagues,3 many other attempts
have been made using a variety of procedures and drugs.
Without referencing all of the literature, it appears that
some type of combined therapy involving BMT and gene

therapy is the best option at this time. In some studies,
multiple injections into the brain, additional drugs and
irradiation before BMT were used but these methods
may not be applicable for a human trial. HSCT in presymptomatic infants predicted to develop KD has shown
the most promise in slowing the course of the disease while
preserving most of cognitive function.32 However, by the
end of the first decade almost all of the treated individuals
show significant peripheral neuropathy. Therefore,
adding a simple gene therapy treatment to HSCT to help
with that aspect would be most advantageous. Studies
in twi mice combining BMT with AAV gene therapy
show great promise in that regard. A number of viral
vectors available for gene therapy trials using different
routes of administration are showing promise in treating
neurodegenerative disorders.33-35 The use of a single iv
injection of AAVrh10-mGALC following HSCT seems
to be the least complicated therapy to implement. Also
HSCT is already considered the “standard of care” for
pre-symptomatic individuals. As shown herein, there is
some flexibility in dosing and timing that would permit
adaption to a human trial.
When the mice received a single iv injection of AAVrh10mGALC in PND10 they showed normal or supranormal
GALC activity in all tissues analyzed, including brain,
spinal cord and sciatic nerve.16 LFB/PAS staining showed
normal myelination in the cerebrum, spinal cord and
sciatic nerve. The median survival of these mice was 72
days with only one living more than 100 days. This was
better than twi mice receiving the iv injection at PND2.14
Clearly twi mice need more than just high GALC activity
to live longer lives. Most infantile human patients treated
before five weeks of age can live at least into the second

Figure 6. Hematoxylin and eosin staining of liver sections. (A) 606-day-old twi mouse treated with BMT plus 1X AAVrh10-mGALC on PND10/11
showing normal morphology. (B) 606-day-old twi treated with BMT and 1X AAVrh10-mGALC on PND10/11 showing dilated sinusoids. (C) 754-day-old twi
mouse treated with BMT plus 1X AAVrh10-mGALC on PND10/11 showing hepatocellular hyperplasia. (D) 472-day-old twi mouse treated with BMT plus 1/2X
AAVrh10-mGALC on PND10/11 showing vacuolar changes. The original images are 10X and the inserts are 20X.
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decade with only HSCT. That treatment only provides a
relatively small amount of GALC activity to the tissues,
therefore the HSCs must provide an additional component
to the treatment. BMT of twi mice has been shown to
slightly lower the psychosine concentration in brain but
not sciatic nerves.44 However, it has been shown to lower
many cytokines and chemokines in brain related to the
inflammatory component of this disease.10 Therefore
combining BMT with iv injection of AAVrh10-GALC
seems to offer the best option for successful treatment of
this disease at this time.
When our initial studies combining BMT with a single
iv injection of AAVrh10-mGALC were published most of
the treated twi mice were still living.17 Additional mice
were treated the same way. Since that time most of those
mice given our published dose of 4 ×1013 gc/kg on PND1011 have died. The median survival is 389 days and with
some living over 500 days. The studies reported here show
that the survival is related to the dose of AAVrh10 vector;
when less vector than used in the original paper was
injected after BMT the survival rate dropped significantly
as shown on Fig. 5A. In addition, the use of lower doses of
vector compared to the standard dose resulted statistically
lower levels of GALC activity in brain, cerebellum and
spinal cord (Fig. 2A). When 4X vector was injected
on PND10 the median survival appeared to increased
further although it did not reach statistical significance.
The higher vector dose resulted in more GALC activity
measured in all nervous tissues although it did not reach
statistical significance in spinal cord and sciatic nerve
(Fig. 2A). These results clearly show that vector dose has a
significant effect on outcome.
The initial studies combining BMT with iv AAVrh10
were done starting at PND9 with busulfan injection,
followed by BMT the next day and viral injection the
following day. The data presented here show that delaying
the viral injection by 5 or 10 days had no significant effect
on the median survival of these mice (Fig. 5B). This may
not be surprising since it has been shown that BMT alone
at PND10 can prolong the lives of twi mice to an average
of about 80 days (Fig. 1) which agrees with the study of
Yeager et al.3 It can also be shown that there is a small
increase in GALC activity in CNS with BMT treatment
alone at least in young mice. However, some earlier
studies were done using irradiation for myelo-suppression
which may disrupt membrane integrity. Also, there may
not be a need for much GALC activity before PND10 in
mice as myelin is just being laid on newly formed axons.
When the time for viral injection is delayed to 30 days
following BMT (PND40), the survival is very similar to
BMT alone, although a few mice lived more than 100 days
(Fig. 5B). After PND20, when the untreated twi mice start
to have tremors, and the sciatic nerves of twi mice treated
only with BMT have abnormal pathology, there is a need
for more GALC activity provided by the viral vector to
correct the myelination in the PNS. Studies injecting the

viral vector 20 days after BMT (PND30) are underway but
the mice are too young to reach a conclusion regarding
the latest time point that can still result in a lifespan near
that of mice that received viral injections on PND10-11,
PND15 and PND20. While starting the BMT around
PND10 followed by viral injection one, five or ten days
later was found to be satisfactory, additional studies
were done delaying both the BMT and viral injection to
PND17-18, PND19-20 and PND21-22. The experiments
show that delaying the start of both treatments resulted in
overall shortened survival (Fig. 5C). While these studies
in mice may have little relevance to the timing of viral
injection in human patients following HSCT, they do
show that timing should be considered when planning a
clinical trial. Our studies show that GALC expression is
detected within 48 hours following iv injection (Table 3).
This is important to the successful treatment of a severe
genetic disease that can have a rapid downhill course.
The studies utilizing heterozygous mice as BM donors
were performed to determine if the outcomes were
comparable to those receiving BM from non-carrier
BM donors. This was done for several reasons. (1) To
determine if the GALC activity in the carrier bone marrow
cells, which might be about half of that from non-carrier
mice, worked as well in prolonging life when combined
with viral gene therapy. (2) To provide some insight as to
the question of whether human related donors who are
carriers of mutations in the GALC gene would be suitable
to be used as an HSC donor. BM cells from heterozygous
donors should still provide the anti-inflammatory
component to the treatment since carriers of KD have
no obvious clinical issues while the viral vector should
provide adequate GALC activity. At least in twi mice, it
appears that using BM cells from carrier mice plus iv gene
therapy did not result in the lifespans observed when BM
cells from non-carrier mice were used (Fig. 5D). However,
it may not be true for all human families. In some families
only a related donor is a good HLA match for the patient
and will be used for HSCT regardless of carrier status.
Also, since there is a high frequency of GALC activity
lowering polymorphisms in the “normal” GALC gene,
some recipients of HSCT are receiving bone marrow cells
from donors with GALC activity within the wide carrier
range.
There is controversy regarding the increase in the
incidence of hepatocellular carcinoma in livers of mice
treated with AAV vectors.40-43 However, in our study there
were no significant pathological changes in mice living
less than 300 days. Most regions of the liver samples
from long-living treated mice appeared normal, however,
some pathological changes were noted in the livers of a
few animals, notably dilated sinusoids, hepatocellular
hyperplasia and presence of vacuolar cytoplasmic
aggregates. While some rare foci of extra-medullary
hematopoiesis were noted, similar changes have been
reported in some patients receiving blood stem cell
BioImpacts, 2020, 10(2), 105-115
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Research Highlights
What is the current knowledge?
√ Krabbe disease (KD) is an autosomal recessive lysosomal
disorder.
√ KD is caused by mutations in the galactocerebrosidase
(GALC) gene.
√ Low GALC activity causes defective myelination in the
peripheral and central nervous systems.
√ Hematopoietic stem cell transplantation (HSCT) in presymptomatic individuals is the only effective treatment.
√ HSCT extends the lives of treated individuals, while most
have difficulty walking by the end of the first decade due to
peripheral neuropathy.
What is new here?
√ Combining BMT with a single iv injection of AAVrh10mGALC greatly extends the lives of twitcher (twi) mice, a
murine model of KD.
√ The dose of viral vector has a profound effect on survival
and measured GALC activity.
√ Delaying both the BMT and the viral injection can shorten
the lifespans of the treated mice.

transplantation and with other hematological disorders.39
However, the examination of liver tissues from over 50
treated mice showed no evidence of neoplastic changes.
Conclusion
It is commonly assumed that earlier is better when
it comes to instituting any type of therapy in human
patients, especially in those disorders involving significant
neurologic involvement. That is done to prevent
pathological changes in the CNS and PNS before they
become irreversible. For this reason newborn screening
(NBS) for some genetic disorders, including KD, has been
started in several states.45 This is being done to identify
individuals who will develop a given disease before
clinical features appear and before there is significant
damage to the developing nervous systems. NBS tests
that were developed to identify individuals at a “high
risk” for developing infantile disease have been mostly
successful. However, there are still issues relating to onset,
predicting the severity of the disease, and timing to start
treatment to be settled. There may be delays in making
a conclusive diagnosis as to the type of disease (infantile,
late infantile, or late-onset) and in finding a suitable donor
for HSCT. The more we can learn from the animal models
related to dosing, timing and donor status, the better the
outcomes for treating human patients will be. It appears
that combining a single iv injection of AAVrh10-GALC
following HSCT, the current standard of care, offers
the best hope for the individuals found to be at risk for
developing KD.
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